Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 9/2005

01-10-2005 | Case Reports

Metastatic prostate cancer with a normal prostate-specific antigen level

Authors: Isabel Ruiz-Martín, César A. Rodríquez-Sánchez, Alberto Ocaña-Fernández, Javier del Valle-Zapico, Diego Soto de Prado-Otero, Juan J. Cruz-Hernández

Published in: Clinical and Translational Oncology | Issue 9/2005

Login to get access
Metadata
Title
Metastatic prostate cancer with a normal prostate-specific antigen level
Authors
Isabel Ruiz-Martín
César A. Rodríquez-Sánchez
Alberto Ocaña-Fernández
Javier del Valle-Zapico
Diego Soto de Prado-Otero
Juan J. Cruz-Hernández
Publication date
01-10-2005
Publisher
Springer-Verlag
Published in
Clinical and Translational Oncology / Issue 9/2005
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/BF02716588

Other articles of this Issue 9/2005

Clinical and Translational Oncology 9/2005 Go to the issue

Original Articles

Sobreimpresión en fracción única con braquiterapia intersticial de alta tasa en el tratamiento conservador del carcinoma de mama

Original Articles

Quality of life in patients with locally advanced head and neck cancer treated with chemoradiotherapy. Comparison of two protocols using the EORTC questionnaires (QLQ-C30, H&N35)

Review

Fármacos antifúngicos. Situación actual y pautas para su administración

Case Reports

Oftalmoplejía completa izquierda por metástasis ósea de cáncer de próstata

News

News

Original Articles

High dose brachytherapy (real time) in patients with intermediate-or high-risk prostate cancer: technical description and preliminary experience
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits